Cargando…

Outpatient (131)I Treatment for a Patient with Graves' Disease Receiving Hemodialysis

A patient presented with hyperthyroidism and end-stage renal disease requiring hemodialysis that was difficult to control despite increased dosages of anti-thyroid drugs. The condition could finally be controlled by (131)I radioactive iodine therapy (RIT) and hemodialysis provided under a hospital-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Miho, Yoshimura Noh, Jaeduk, Sugino, Kiminori, Ito, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173499/ https://www.ncbi.nlm.nih.gov/pubmed/27853074

Ejemplares similares

Clinical Course of Euthyroid Subjects With Positive TSH Receptor Antibody: How Often Does Graves’ Disease Develop?
por: Suzuki, Nami, et al.
Publicado: (2021)

Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves’ disease
por: Suzuki, Nami, et al.
Publicado: (2018)

Frequency of Adverse Events of Antithyroid Drugs Administered during Pregnancy
por: Yoshihara, Ai, et al.
Publicado: (2014)

Exposure to Propylthiouracil in the First Trimester of Pregnancy and Birth Defects: A Study at a Single Institution
por: Yoshihara, Ai, et al.
Publicado: (2021)

The Potential Impact of the COVID-19 Pandemic on Clinical Management of Thyroid Disorders in Japan
por: Inoue, Kosuke, et al.
Publicado: (2021)

Delayed Follow-up Visits and Thyrotropin Among Patients With Levothyroxine During the COVID-19 Pandemic
por: Inoue, Kosuke, et al.
Publicado: (2021)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine ((131)I) treatment
por: Xing, Yu-Zhuo, et al.
Publicado: (2020)

Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease
por: Jhummon, Navina Priya, et al.
Publicado: (2013)

Subclinical Hypothyroidism after (131)I-Treatment of Graves’ Disease: A Risk Factor for Depression?
por: Yu, Jing, et al.
Publicado: (2016)

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease
por: Zhang, Ruiguo, et al.
Publicado: (2017)

A case report of (131)I therapy for Graves’ disease patient with hemiagenesis
por: Liu, Xuehui, et al.
Publicado: (2019)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Efficacy of radioactive iodine treatment of graves’ hyperthyroidism using a single calculated (131)I dose
por: Wong, Ka Kit, et al.
Publicado: (2018)

Factors Predicting Treatment Failure in Patients Treated with Iodine-131 for Graves’ Disease
por: Manohar, Kuruva, et al.
Publicado: (2013)

I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening
por: Tran, Phuong, et al.
Publicado: (2010)

Received dose variability after administration of I‐131 for treatment of hyperthyroidism in cats
por: Busser, Suzanne, et al.
Publicado: (2021)

Role of Surgery in Patients with Stage IE Primary Thyroid MALT Lymphoma Staged by a Modified Classification System: The Tokyo Classification
por: Saito, Yoshiyuki, et al.
Publicado: (2023)

SUN-510 Prolonged RAIA Induced Thyroiditis After 131 I Therapy for Graves’ Hyperthyroidism
por: Aljaberi, Asma Khaled, et al.
Publicado: (2020)

Finding the best effective way of treatment for rapid I-131 turnover Graves’ disease patients: A randomized clinical trial
por: Thamcharoenvipas, Siwaporn, et al.
Publicado: (2019)

Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience
por: Bhatia, Nisha, et al.
Publicado: (2023)

Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of (131)iodine treatment
por: Wang, Renfei, et al.
Publicado: (2017)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism
por: Doi, Suhail AR, et al.
Publicado: (2001)

Determination of administered activities for the treatment of Graves' disease with iodine-131: Proposition of a simplified dosimetric procedure
por: Soli, Idrissa Adamou, et al.
Publicado: (2021)

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy
por: Yu, Feng, et al.
Publicado: (2021)

I-131 uptake in fat necrosis of the breast
por: Itani, Malak, et al.
Publicado: (2016)

Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves’ disease after (131)Iodine treatment
por: Zhang, Li-Hua, et al.
Publicado: (2016)

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
por: Ozeki, Tomoko, et al.
Publicado: (2019)

Effect of (131)I with and without artificial liver support system in patients with Graves’ disease and severe liver dysfunction: A retrospective study
por: Rao, Maohua, et al.
Publicado: (2022)

Painless destructive thyroiditis in a patient with resistance to thyroid hormone: a case report
por: Nagamine, Tomoko, et al.
Publicado: (2019)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Corrigendum: Effect of 131 I with and without artificial liver support system in patients with Graves’ disease and severe liver dysfunction: A retrospective study
por: Rao, Maohua, et al.
Publicado: (2023)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Unexpected Uptake by the Gallbladder in Post-Ablative I-131 Scan
por: Ünal, Kemal, et al.
Publicado: (2015)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

(131)I-Caerin 1.1 and (131)I-Caerin 1.9 for the treatment of non-small-cell lung cancer
por: Liu, Na, et al.
Publicado: (2022)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7sajaprg7g652503mjbnkpgbce